Physiol Rev. 2013 Oct;93(4):1743-802. doi: 10.1152/physrev.00006.2013.
After the onset of ischemia, cardiac or skeletal muscle undergoes a continuum of molecular, cellular, and extracellular responses that determine the function and the remodeling of the ischemic tissue. Hypoxia-related pathways, immunoinflammatory balance, circulating or local vascular progenitor cells, as well as changes in hemodynamical forces within vascular wall trigger all the processes regulating vascular homeostasis, including vasculogenesis, angiogenesis, arteriogenesis, and collateral growth, which act in concert to establish a functional vascular network in ischemic zones. In patients with ischemic diseases, most of the cellular (mainly those involving bone marrow-derived cells and local stem/progenitor cells) and molecular mechanisms involved in the activation of vessel growth and vascular remodeling are markedly impaired by the deleterious microenvironment characterized by fibrosis, inflammation, hypoperfusion, and inhibition of endogenous angiogenic and regenerative programs. Furthermore, cardiovascular risk factors, including diabetes, hypercholesterolemia, hypertension, diabetes, and aging, constitute a deleterious macroenvironment that participates to the abrogation of postischemic revascularization and tissue regeneration observed in these patient populations. Thus stimulation of vessel growth and/or remodeling has emerged as a new therapeutic option in patients with ischemic diseases. Many strategies of therapeutic revascularization, based on the administration of growth factors or stem/progenitor cells from diverse sources, have been proposed and are currently tested in patients with peripheral arterial disease or cardiac diseases. This review provides an overview from our current knowledge regarding molecular and cellular mechanisms involved in postischemic revascularization, as well as advances in the clinical application of such strategies of therapeutic revascularization.
在发生缺血后,心脏或骨骼肌会经历一系列分子、细胞和细胞外反应,这些反应决定了缺血组织的功能和重塑。与缺氧相关的途径、免疫炎症平衡、循环或局部血管祖细胞,以及血管壁内血流动力学变化,触发了所有调节血管稳态的过程,包括血管生成、血管生成、动脉生成和侧支生长,这些过程协同作用,在缺血区域建立功能性血管网络。在缺血性疾病患者中,大多数参与血管生长和血管重塑激活的细胞(主要涉及骨髓来源的细胞和局部干细胞/祖细胞)和分子机制,由于纤维化、炎症、灌注不足和内源性血管生成和再生程序的抑制等有害微环境而明显受损。此外,心血管危险因素,包括糖尿病、高胆固醇血症、高血压、糖尿病和衰老,构成了有害的宏观环境,参与了这些患者群体中观察到的缺血后再血管化和组织再生的中止。因此,刺激血管生长和/或重塑已成为缺血性疾病患者的一种新的治疗选择。许多基于不同来源的生长因子或干细胞/祖细胞给药的治疗性再血管化策略已经提出,并正在患有外周动脉疾病或心脏病的患者中进行测试。这篇综述概述了我们目前对缺血后再血管化涉及的分子和细胞机制的了解,以及这些治疗性再血管化策略在临床应用方面的进展。